Amphastar Pharmaceuticals (AMPH) Retained Earnings (2013 - 2026)

Amphastar Pharmaceuticals' Retained Earnings history runs 14 years deep, the most recent figure standing at $673.3 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 13.34% year-over-year to $673.3 million in Q1 2026; TTM through Mar 2026 was $673.3 million, a 13.34% increase from a year earlier, with the FY2025 full-year figure at $666.9 million, up 31.95% from the prior year.
• Retained Earnings grew to $673.3 million in Q1 2026 per AMPH's latest filing, from $666.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at $673.3 million in Q1 2026 and bottomed at -$9.9 million in Q3 2022.
• The 5-year median for Retained Earnings is $456.6 million (2023), against an average of $393.8 million.
• Across the five-year window, Retained Earnings slumped 102.41% in 2022 and surged 6402.59% in 2023, its largest moves.
• Year by year, Retained Earnings stood at $271.7 million in 2022, then soared by 50.62% to $409.3 million in 2023, then rose by 23.49% to $505.4 million in 2024, then soared by 31.95% to $666.9 million in 2025, then climbed by 0.96% to $673.3 million in 2026.
• Per Business Quant, the three latest AMPH Retained Earnings figures stand at $673.3 million (Q1 2026), $666.9 million (Q4 2025), and $642.5 million (Q3 2025).